Santiago González-Santiago

Author

Also Known As

González-Santiago, Santiago, S González-Santiago, S. Gonzalez-Santiago, S. González-Santiago, S. González‐Santiago, Santiago Gonzalez-Santiago, Santiago González-Santiago, the SEOM Hereditary Cancer Working Group

Publications

920

Citations

H-Index

Concepts

All Affiliations

Hospital San Pedro de Alcántara Vall d'Hebron Hospital Universitari Fundación Instituto Valenciano de Oncología Hospital Universitario Virgen del Rocío Institut Català d'Oncologia

About

Santiago González-Santiago is an author at Hospital San Pedro de Alcántara specializing in breast cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	517
2	Health Sciences	1	1	13
3	Public Health	1	1	20
4	Diabetes	1	1	13
5	Molecular Medicine	1	1	20

Santiago González-Santiago

Publications

803

Citations

H-Index

Page 1

	Year	Citations
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer Nicoletta Colombo, Gloria S. Huang, Giovanni Scambia, Journal of Clinical Oncology	2018	95
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer Antonio Llombart‐Cussac, Begoña Bermejo, Cristian Villanueva, Breast Cancer Research and Treatment Breast OncologyOncologyPhase IiSolti NeoparpPathology	2015	40
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain I. Esteban, Marta Vilaró, Encarna Adrover, Psycho-Oncology	2018	36
SEOM clinical guidelines on cardiovascular toxicity (2018) Juan Antonio Virizuela, Ana Martín‐Garcia, R. de las Peñas, Clinical & Translational Oncology	2019	33
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study) Santiago González-Santiago, Cristina Saura, Eva Ciruelos, Breast Cancer Research and Treatment Neopetra StudyBreast OncologyOncologyDual Her2 BlockadeReal-world Effectiveness	2020	30
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study Zsuzsanna Kahán, Miguel Gil‐Gil, Manuel Ruíz‐Borrego, European Journal of Cancer	2021	28
CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen Santiago González-Santiago, Ruth Zárate, Juan de la Haba-Rodríguez, Journal of Clinical Oncology Breast OncologyGenetic EpidemiologyHuman PolymorphismPathologyPharmacotherapy	2007	20
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial Antonio Llombart‐Cussac, José Manuel Pérez-García, Manuel Ruíz Borrego, EClinicalMedicine	2024	19
Analysis of Lynch Syndrome Mismatch Repair Genes in Women with Endometrial Cancer Izaskun Rubio, Eduardo Ibáñez-Feijoo, Leire Andrés, Oncology	2016	18

Page 1